

## Review Article

# Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial

Hong Ding, Shu Liu, Ke-Xin Zhao, Jie Pu, Ya-Fei Xie, and Xiao-Wei Zhang 

Department of Cardiology, Lanzhou University Second Hospital, Lanzhou, China

Correspondence should be addressed to Xiao-Wei Zhang; xwzhang@lzu.edu.cn

Received 28 December 2021; Revised 20 February 2022; Accepted 10 March 2022; Published 30 April 2022

Academic Editor: Thereza Maria Magalhães Moreira

Copyright © 2022 Hong Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hypertension induces both structural and functional changes in blood vessels, thereby increasing endothelial dysfunction, which in turn, contributes to an increase in blood pressure. A popular and widely used noninvasive tool, flow-mediated dilation (FMD), is used to examine peripheral artery endothelium-dependent dilation. This study aimed to compare the efficacies of different classes of antihypertensive agents based on their effects on FMD. PubMed, Embase, and Cochrane Library were queried till November 1, 2020. Comparative studies on the efficacies of two or more antihypertensive agents or placebos for hypertensive patients were included. The outcomes were variations in mean systolic and diastolic blood pressure. Two reviewers independently reviewed and filtered the literature and extracted the data; the Cochrane “risk of bias” method was used to evaluate the methodological quality of the randomized controlled trials. A network meta-analysis was performed using Stata 15.0 software with a total of 49 studies. Subgroup analysis based on age and duration of treatments was performed. As compared to the placebo group, patients receiving the antihypertensive drugs exhibited significantly enhanced FMD (ARB + CCB: 4.01%, 95% CI, 0.92–7.11%,  $p < 0.001$ ; ACEI + ARB: 2.81%, 95% CI, 1.19–4.43%,  $p < 0.001$ ; ACEI: 2.55%, 95% CI, 1.34–3.77%,  $p < 0.001$ ; ARB: 2.22%, 95% CI, 1.05–3.38%,  $p < 0.001$ ;  $\beta$ -blocker: 2.23%, 95% CI, 0.93–3.52%,  $p < 0.001$ ). In the SUCRA curve for network meta-analysis, the combination of CCB and ARB was found to be the most effective in increasing FMD (SUCRA = 89.0%), followed by ACEI monotherapy (SUCRA = 74.2%). ARB combined with CCB was superior in improving the endothelial function measured as the FMD; ACEI monotherapy was the most effective treatment among the antihypertension medications. There were no significant differences between antihypertensive drug-based monotherapies.

## 1. Introduction

Hypertension contributes significantly to the total disease burden and is an important cause of mortality. A CHS study (2012–2015) reports that the prevalence of hypertension among Chinese residents ( $\geq 18$  years old) is 27.9% [1]. Elevated blood pressure (BP) has an intimate and continuous association with cardiovascular (CV) and renal events [2]. Estimates suggest that, in 2025, approximately 1.5 billion adults would be hypertensive [2]. Based on epidemiological survey, the prevalence of hypertension would be over 150 million in central and Eastern Europe [2]. Hypertension induces structural and functional changes in blood vessels that increase endothelial dysfunction and subsequently may

also contribute to an increase in the blood pressure [3]. Thus, the possibility of ameliorating the impaired endothelial function is an important target for the antihypertensive therapy [4]. Flow-mediated dilation (FMD) is the most frequently noninvasive technique for the evaluation of endothelial function by brachial ultrasound during reactive hyperemia [5].

Knowledge of the optimal antihypertension medications for the prevention of FMD will be crucial for decision-making in clinical settings. Moreover, the identification of the most effective treatments for controlling hypertension and management of impaired endothelial function is imperative to guide clinicians and decrease the global burdens of cardiovascular diseases.

Previous meta-analyses have examined the efficacy of antihypertension treatments for improving the FMD status using [6, 7] pairwise comparisons of only two classes of antihypertension medications; however, pairwise meta-analysis does not enable comparisons among multiple classes of medications. To provide an updated perspective on the comparative efficacies of antihypertension medications, we performed a network meta-analysis to compare the reported effects of different classes of antihypertension medications that are in current use for increasing FMD. FMD is strictly dependent on the brachial artery diameter. Therefore, we also performed a network meta-analysis to examine the drug-induced changes on comparisons of the brachial artery diameter (BAD) in the literature.

## 2. Materials and Methods

**2.1. Search Strategy.** Electronic databases including PubMed, Cochrane Library, Embase, and ClinicalTrials.gov were systematically queried for English versions of the publications until November 1, 2020. PICO criteria were as follows: (1) population: hypertensive adults with the mean age of 18 years or above; (2) intervention and comparison: at least two different classes of antihypertension medications or one antihypertension medication intervention with placebo controlled intervention compared in each trial; (3) outcome: flow-mediated dilation and brachial artery diameter. We used a combination of Medical Subject Headings (MeSH) terms and words to retrieve the relevant articles on directive comparisons on the efficacies of different classes of antihypertensive medications in FMD of hypertensive patients. The search terms used were as follows: hypertension AND flow-mediated dilation AND antihypertension medications (refer to Appendix). All the bibliographies of the selected articles were screened to collect the additional relevant articles. When the full-text articles were not accessible through the electronic databases, we contacted corresponding authors by phone or through e-mail. Gray literature has been retrieved, but the literature is not related, and not included.

**2.2. Study Inclusion Criteria.** The titles and abstracts were construed by two independent reviewers and evaluated for the inclusion and exclusion criteria through EndNote software and duplicates were removed automatically. The third reviewer was consulted in case of discrepancies regarding the study selection, which was then resolved. Pre-specific selection criteria include the following: (1) the studies were prospective, randomized, controlled trials; (2) patients > 18 years; (3) adult patients satisfying the diagnosis criteria of hypertension (SBP  $\geq$ 140 mmHg or DBP  $\geq$ 90 mmHg) or previously diagnosed with hypertension; (4) random assignment to different classes of antihypertensive agents, and (5) the studies reporting the available index of FMD. After assessment of the full text, the articles that met the selection criteria and provided sufficient data were included for further analysis.

**2.3. Data Extraction and Quality Assessment.** According to the predefined selection criteria, data were extracted independently by the two reviewers. The articles with not available outcome data were excluded. Any inconsistencies were resolved by discussion, and when necessary, cross-validated with the authors of the trial study. The following data were extracted from each trial: author, country, sample size, age, BMI, sex, antihypertensive medication, dose, time, blood pressure, FMD methodology, and outcomes measured. The methodological quality of each study was evaluated by the two reviewers according to guidelines in chapter 8 of the Cochrane handbook [8–10].

**2.4. Statistical Analysis.** The network meta-analysis in our study was performed using a Bayesian random-effects generalized linear model. The results were reported as the standard mean deviation of 95% confidence intervals (CI) after the comparison of all intervention modes. The hypothesis test was a *U*-test; the value of  $P < 0.05$  was considered statistically significant. In a closed-loop, the inconsistencies between direct and indirect evidence were evaluated by the node splitting method. The efficacy of the intervention was ranked based on the surface values under the cumulative ranking (SUCRA) curve [11]. Finally, a funnel plot was generated to detect potential the publication bias. The sensitivity was analyzed according to random effects model. We performed a subgroup analysis based on the age and duration of treatments. The mean age of participants was used to classify the studies into two groups, namely, trials that had enrolled patients aged  $\leq 55$  years and trials with patients aged  $> 55$  years. Based on the treatment duration, the studies were categorized based on antihypertension medications. All statistical analyses were performed using Review Manager 5.3 (The Cochrane Collaboration) and Stata 15.1.

## 3. Results

**3.1. Characteristics of the Included Studies.** 49 randomized controlled trials (RCTs) comprising 2646 patients suffering from antihypertension and treated with corresponding antihypertensive agents for improving their FMD status were included to determine the contributions of these agents in enhancing FMD. The studies included in our meta-analysis were all RCTs, published until November 2020. The studies were conducted in Italy [12–19], Germany [20], China [21–26], Turkey [27–33], UK [34], Brazil [35–37], Greece [38], Denmark [39], Korea [40–45], Bulgaria [46], USA [47], Chile [48], and Japan [49–60]. A flow diagram depicting the inclusion process of these studies is shown in Figure 1. Table 1 presents the basic characteristics of the included trials and the demographic data of the participants.

**3.2. Quality of the Included Studies.** The quality of all included RCTs was assessed using the tools of the Cochrane Collaboration. Randomization was performed in all RCTs. However, only six studies described the method of randomization, which included sealed envelopes, random




FIGURE 1: PRISMA diagram of the clinical review search strategy.

number table, and randomly permuted blocks. RCTs included in this study provided complete data and but not provide information on other potential biases. The qualities of the article evaluated are as follows (Figures 2 and 3).

**3.3. Network Geometry.** As shown in the network diagram, each point represents a drug, and a directly connected line segment between the two points, indicated that a direct comparison between the two drugs was reported. The size of the nodes and the width of the lines are directly proportional to the number of tests. Network evidence for the comparisons between the different antihypertensive agents is shown in Figure 4.

**3.4. Testing for Inconsistency.** The inconsistency test showed that the comparison could be valued for consistency,  $\chi^2 = 17.35$ ,  $P = 0.1368$  in FMD (Figures 5(a) and 6(a)) and  $\chi^2 = 3.01$ ,  $P = 0.390$  in BAD (Figures 5(b) and 6(b)). Based on the  $P$ -values, the results of inconsistency tests between direct and indirect treatment comparisons for mixed treatment comparison showed no general inconsistencies

between treatment effects on each outcome (all  $P > 0.05$ , Tables 2 and 3).

**3.5. Effect of Antihypertensive Medications on FMD and BAD.** Compared with the placebo group, the antihypertensive drugs significantly enhance FMD [angiotensin receptor blocker (ARB) + calcium channel blockers (CCB): 4.01%, 95% CI, 0.92–7.11%,  $p < 0.001$ ; angiotensin-converting enzyme inhibitors (ACEI) + ARB: 2.81%, 95% CI, 1.19–4.43%,  $p < 0.001$ ; ACEI: 2.55%, 95% CI, 1.34–3.77%,  $p < 0.001$ ; ARB: 2.22%, 95% CI, 1.05–3.38%,  $p < 0.001$ ];  $\beta$ -blocker: 2.23%, 95% CI, 0.93–3.52%,  $p < 0.001$ ). No significant differences between monotherapy (Figure 7(a)). In the SUCRA curve for network meta-analysis in FMD, the combination of CCB and ARB was found to be the most effective agent for increasing FMD (SUCRA = 89.0%), followed by ACEI mono-therapy (SUCRA = 74.2%) (Figure 8(a)). In BAD, no statistically significant differences among antihypertension medications were observed (Figure 7(b)). The SUCRA curve for network meta-analysis demonstrated that the most effective antihypertension medication was CCB; it could increase BAD substantially (SUCRA = 90.6%, Figure 8(b)).

TABLE 1: Characteristics of the studies included in this Meta-analysis.

Author, year	Country	Antihypertensive drug	Dose	n	Time	Age (year)	BMI	Sex (M/F)	Durations (year)	SBP (mmHg)	DBP (mmHg)	Measurement
Iwatsubo et al., 1997 [50]	Japan	Temocapril	2 or 4 mg	15	6 m	63 ± 3	21.1 ± 0.5	4/11	NA	160 ± 4	165 ± 5	Vascular
Mutesan et al., 1999 [12]	Italy	Amlodipine Nifedipine HCTZ	2.5 or 5 mg NA NA	11 10 10	6 m 2 m 2 m	61 ± 2 56 ± 2 56 ± 7	22.9 ± 0.5 NA NA	3/8 7/3 7/3	NA NA NA	94 ± 2 161 ± 16 154 ± 11	94 ± 3 102 ± 9 98 ± 4	Vascular Vascular ultrasonography
Akimi, 2001	Japan	Quinapril Nitrendipine	20 mg 10 mg	15 11	3 m 3 m	60 ± 11 58 ± 12	NA NA	9/6 4/7	NA NA	165 ± 16 160 ± 15	98 ± 6 92 ± 5	Vascular ultrasonography
Ghiadoni et al., 2001 [13]	Italy	Nifedipine	20 mg	32	2 h	52.1 ± 10.1	NA	20/12	NA	152.7 ± 10.7	101.7 ± 8.8	Vascular
Fang et al., 2002 [21]	China	Captopril Nifedipine Ramipril	50 mg 5 mg 10 mg	32 47 49	2 h 3 m 3 m	50.9 ± 9.6 57 ± 8 56 ± 6	NA NA NA	20/12 25/22 27/22	NA NA NA	150.5 ± 10.3 164 ± 16 162 ± 14	100.5 ± 8.8 96 ± 8 98 ± 9	ultrasonography Vascular ultrasonography
Ghiadoni et al., 2003 [14]	Italy	Nifedipine Amlodipine Atenolol Nebivolol Telmisartan	30–60 mg 5–10 mg 5–100 mg 5–10 mg 80–160 mg	28 28 29 28 29	6 m 6 m 6 m 6 m 6 m	52 ± 11 53 ± 8 53 ± 9 53 ± 8 50 ± 9	NA NA NA NA NA	17/11 17/11 18/11 17/11 18/11	NA NA NA NA NA	153 ± 8 152 ± 9 156 ± 10 152 ± 9 151 ± 10	102 ± 2 98 ± 9 99 ± 8 98 ± 9 100 ± 7	Vascular ultrasonography
Mumakata et al., 2003	Japan	Perindopril Amlodipine Benidipine Nifedipine Temocapril Cirazapril	2–4 mg 2.5 mg 4 mg 10 mg 2 mg 0.5 mg	28 10 9 5 9 3	6 m 12 m 12 m 12 m 12 m 12 m	51 ± 11 55 ± 2	NA NA	18/10 8/16	NA NA	153 ± 9 172 ± 4	100 ± 6 101 ± 3	Vascular Ultrasonography
Sekuri et al., 2003 [27]	Turkish	Perindopril + indapamide	2 mg + 0.625 mg	29	6 m	54.5 ± 9.5	NA	12/17	NA	155.2 ± 10.3	96.6 ± 6.1	Vascular ultrasonography
Tezcan et al., 2003 [28]	Turkey	Enalapril	5–40 mg	9	6 m	38.3 ± 9	25.2 ± 4.0	4/5	2.3 ± 2.2	147.4 ± 10.1	96.6 ± 7.0	Vascular ultrasonography
Yavuz et al., 2003 [29]	Turkey	Enalapril Losartan	5–40 mg 50–100 mg	12 12	6 m 6 m	38.6 ± 7.9 42.2 ± 12.8	24.7 ± 4.9 24.4 ± 4.5	4/8 4/7	3.1 ± 3.7 3.3 ± 3	149 ± 11 150 ± 21	98 ± 7 100 ± 5	Vascular ultrasonography
Chung et al., 2004 [34]	UK	Losartan HCTZ	50–100 mg 12.5–25 mg	21 19	12 w 12 w	55.9 ± 11.8	28.3 ± 4.7	28/12	NA	164 ± 15 165 ± 18	97 ± 11 93 ± 13	Vascular ultrasonography
Koh et al., 2004 [45]		Losartan Placebo	100 mg NA	47 2	2 m 2 m			5/5	9 ± 6	147 ± 3 145 ± 2	91 ± 1 90 ± 1	Vascular ultrasonography
Yamanari et al., 2004 [49]	Japan	Enalapril Manidipine + metoprolol	10 mg 20 + 60 mg	10 11	6 m 6 m	65 ± 10 66 ± 9		7/4	8 ± 5	NA NA	NA NA	Vascular Ultrasonography
Morimoto et al., 2006 [53]	Japan	Amlodipine Telmisartan	5 mg 40 mg	22 21	24 w 24 w	58 ± 2 56 ± 2	23.9 ± 0.7 24.7 ± 0.8	9/13 9/12	5 ± 1 7 ± 1	163 ± 3 162 ± 5	93 ± 1 95 ± 4	Vascular ultrasonography
Souza-Barbosa et al., 2006 [35]	Brazil	HCTZ Quinapril Irbesartan Quinapril + irbesartan	20–25 mg 20 mg 150 mg 20 + 150 mg	18 16 14 15	12 w 12 w 12 w 12 w	49.4 ± 7.9 48.8 ± 8.6 50.3 ± 7.5 49.9 ± 5.1	26.4 ± 3.3 26.3 ± 2.5 24.5 ± 3.5 26.6 ± 2.8	7/11 7/9 6/9 6/8	NA NA NA NA	148 ± 11 150 ± 14 168 ± 15 164 ± 17	92 ± 9 94 ± 11 90 ± 12 90 ± 11	Vascular ultrasonography
Aznaouridis et al., 2007 [38]	Greece	Captopril Quinapril Telmisartan	25 mg 20 mg 80 mg	25 25 25	2 h 2 h 2 h	57.4 ± 9.6 56.8 ± 10.4 56.3 ± 8.9	28.0 ± 4.0 28.1 ± 4.2 28.3 ± 3.9	10/15 13/12 12/13	2 (1–6.5) 5 (1–12) 2 (1–7)	148.8 ± 18.9 146.6 ± 15.9 148.7 ± 19.2	89.4 ± 9.4 92.9 ± 12.2 95.9 ± 15.3	Vascular ultrasonography

TABLE 1: Continued.

Author, year	Country	Antihypertensive drug	Dose	n	Time	Age (year)	BMI	Sex (M/F)	Durations (year)	SBP (mmHg)	DBP (mmHg)	Measurement
Benndorf et al., 2007 [20]	Germany	Telmisartan	40-80 mg	12	6 w	59.0 ± 7	23.0 ± 3.0	7/5	NA	NA	NA	Vascular
		Nisoldipine	10 mg	13	6 w	56.9 ± 8	27.1 ± 4.1	6/7	NA	NA	NA	NA
Buus et al., 2007 [39]	Denmark	Telmisartan + Nisoldipine	40 + 10 mg	12	6 w	59.6 ± 8	24.5 ± 4.2	7/5	NA	NA	NA	Vascular
		Perindopril	4 mg	15	12 m	49 ± 2	27.1 ± 0.5	10/5	NA	NA	160 ± 4	105 ± 2
Ghiadoni et al., 2007 [15]	Italy	Atenolo	50 mg	16	12 m	51 ± 2	26.8 ± 0.6	13/3	NA	158 ± 3	105 ± 1	ultrasonography
		Ramipril	5 mg	21	24 w	NA	NA	NA	NA	163 ± 13	101 ± 6	Vascular
Koh et al., 2007 [40]	Korea	Ramipril	10 mg	21	24 w	NA	NA	NA	NA	163 ± 13	101 ± 6	ultrasonography
		Ramipril	10 mg	34	2 m	46 ± 2	25.24 ± 0.43	NA	NA	155 ± 1	95 ± 1	Vascular
Morimoto et al., 2007 [54]	Japan	Candesartan	16 mg	34	2 m	58 ± 2	25.22 ± 0.43	NA	NA	156 ± 1	95 ± 1	ultrasonography
		Ramipril + Candesartan	10 + 16 mg	34	2 m	58 ± 2	25.26 ± 0.44	NA	NA	157 ± 1	96 ± 1	Vascular
Pasini et al., 2007 [16]	Italy	Amlodipine	25 mg	25	24 w	57 ± 3	24.2 ± 0.7	12/13	5 ± 1	161 ± 3	96 ± 1	Vascular
		Cilnidipine	10 mg	25	24 w	51.5 ± 8.2	24.5 ± 0.9	14/11	6 ± 1	160 ± 3	97 ± 3	ultrasonography
Hirooka et al., 2008 [55]	Japan	Zofenopril	15-30 mg	15	8 w	52.2 ± 13.9	25.8 ± 2.2	7/8	NA	152.8 ± 6.7	99.2 ± 4.1	ultrasonography
		Ramipril	2.5-5 mg	15	8 w	48.6 ± 12.5	24.8 ± 2.6	8/7	NA	152.7 ± 7.6	98.1 ± 4.2	Vascular
Kosch et al., 2008 [30]	Turkey	Atenolol	50-100 mg	15	8 w	57 ± 3	25.4 ± 1.4	7/8	NA	150.8 ± 5.5	99.4 ± 3.9	ultrasonography
		Valsartan	80 mg	9	30 d	66 ± 3	25.7 ± 1.5	2/7	NA	NA	NA	Vascular
Korkmaz et al., 2008 [31]	Turkey	Amlodipine	5 mg	9	30 d	45.4 ± 5	24.5 ± 1.1	4/5	NA	NA	NA	ultrasonography
		Valsartan	80 mg	35	12 w	46.2 ± 6	29 ± 5	18/17	31 ± 32 (m)	149.2 ± 13.3	97.5 ± 7	Vascular
Pasini et al., 2008 [17]	Italy	Metoprolol	50 mg	33	12 w	53 ± 9	28.2 ± 5	19/14	33 ± 34 (m)	152.9 ± 16.7	98.5 ± 7	ultrasonography
		Quinapril	20 mg	27	4 w	52 ± 9	30 ± 5	13/14	NA	159 ± 14	94 ± 5	Vascular
Yamada et al., 2008 [56]	Japan	Nebivolol	5 mg	27	4 w	55.9 ± 10	30 ± 4	12/15	NA	163 ± 16	97 ± 8	ultrasonography
		Atenolol	100 mg	20	4 w	65 ± 9	26.8 ± 3.3	8/12	NA	152.1 ± 7.9	96.3 ± 4.7	Vascular
Ghiadoni et al., 2009 [18]	Italy	Nebivolol	5 mg	20	4 w	49.1 ± 9	24.0 ± 2.5	16/5	NA	131 ± 13	79 ± 10	ultrasonography
		Azelinidipine	16 mg	21	8 w	48.1 ± 10.7	26.5 ± 2.1	24/7	NA	160 ± 5	100 ± 3	Vascular
Jung et al., 2009 [41]	Korea	Benidipine	4 mg	31	24 w	57.2 ± 10.5	26.4 ± 2.4	26/5	NA	160 ± 6	101 ± 4	ultrasonography
		Perindopril	2-5 mg	31	24 w	61 ± 6	24.7 ± 2.4	36/3	NA	153 ± 15	90 ± 13	Vascular
Kim et al., 2009 [42]	Korea	Telmisartan	80 mg	39	8 w	57.9 ± 9.7	28 ± 5.2	18/7	NA	136.4 ± 11.2	82.2 ± 7.4	ultrasonography
		Cilnidipine	10 mg	44	6 m	57.2 ± 10.5	25.27 ± 0.31	29/16	NA	135.7 ± 12.2	83.6 ± 7.8	Vascular
Koh et al., 2009 [43]	Korea	Cilnidipine + captopril	10 mg + 25 mg	43	6 m	52 ± 2	28 ± 5.2	23/21	NA	154 ± 1	95 ± 1	ultrasonography
		Amlodipine	10 mg	45	8 w	45.3 ± 11.5	27.7 ± 3.9	1/10	NA	152.4 ± 18.5	99.3 ± 9.3	Vascular
Simova et al., 2009 [46]	Bulgaria	Nebivolol	5 mg	14	8 w	45 ± 5	27.0 ± 2.9	4/7	NA	NA	NA	ultrasonography
		Bisoprolol	5 mg	11	8 w	44 ± 7	26.9 ± 3.6	7/4	NA	NA	NA	Vascular
Sozen, 2009	Turkey	Irbesartan	300 mg	11	6 w	45 ± 8	25.6 ± 3.0	6/5	NA	NA	NA	ultrasonography
		Valsartan	160 mg	11	6 w	77 ± 6	NA	3/11	NA	151 ± 7	79 ± 8	Vascular
Yamanari et al., 2009 [57]	Japanese	Fosinopril	10 mg	11	6 w	77 ± 6	NA	3/11	NA	149 ± 10	78 ± 7	ultrasonography
		Quinapril	20 mg	14	16 w	77 ± 6	NA	3/11	NA	149 ± 10	78 ± 7	ultrasonography
		Spironolactone	25 mg	14	16 w	77 ± 6	NA	3/11	NA	149 ± 10	78 ± 7	ultrasonography
		Chlorthalidone	25 mg	14	16 w	77 ± 6	NA	3/11	NA	149 ± 10	78 ± 7	ultrasonography

TABLE 1: Continued.

Author, year	Country	Antihypertensive drug	Dose	n	Time	Age (year)	BMI	Sex (M/F)	Durations (year)	SBP (mmHg)	DBP (mmHg)	Measurement
Koh et al., 2010 [44]	Korea	Atenolol	100 mg	31	8 w	49 ± 2	24.90 ± 0.41	21/10	NA	156 ± 1	96 ± 1	Vascular ultrasonography
		Amlodipine	10 mg	30	8 w	51 ± 2	25.11 ± 0.36	19/11	NA	155 ± 1	96 ± 1	
		Hydrochlorothiazide	50 mg	31	8 w	48 ± 2	25.30 ± 0.44	20/11	NA	153 ± 1	94 ± 1	
		Ramipril	10 mg	30	8 w	46 ± 1	25.14 ± 0.45	20/10	NA	155 ± 1	94 ± 1	
Huang et al., 2010 [22]	China	Candesartan	16 mg	31	8 w	47 ± 2	25.21 ± 0.43	22/9	NA	156 ± 1	94 ± 1	Vascular ultrasonography
		Carvedilol	10 mg	28	6 m	60.2 ± 11.6	NA	18/10	NA	156 ± 7	90 ± 2	
		Metoprolol	50 mg	29	6 m	62.1 ± 13.8	NA	17/12	NA	158 ± 4	89 ± 3	
		Metoprolol	50 mg	12	4 w	56 ± 2	28 ± 1	NA	NA	138 ± 2	80 ± 2	
Heffernan et al., 2011 [47]	USA	Atenolol	50 mg	12	4 w				NA	141 ± 2	79 ± 2	Vascular ultrasonography
		Barnidipine	10 mg	20	24 w	50 ± 9.5	26.8 ± 4	15/4	NA	147 ± 12	96 ± 8	
		HCTZ	12.5 mg	20	24 w	47 ± 9.8	26.4 ± 3	16/4	NA	142 ± 11	93 ± 8	
		Olmesartan	20 mg	15	4 w	55 ± 11	25.8 ± 4.2	13/2	NA	152 ± 15	95 ± 10	
Muisan et al., 2011 [19]	Italy	Amlodipine	5 mg	16	4 w	56 ± 11	24.4 ± 3.1	14/2	NA	149 ± 21	91 ± 14	Vascular ultrasonography
		Olmesartan	NA	20	48 w	NA	24.4 ± 2.6	NA	NA	159.5 ± 14.6	95.3 ± 10.2	
		Eplerenone	NA	20	48 w	NA	24.2 ± 2.7	NA	NA	159.8 ± 14.4	96.1 ± 10.5	
		Nifedipine	NA	20	48 w	NA	24.3 ± 2.5	NA	NA	159.7 ± 13.9	95.4 ± 9.8	
Fujimura et al., 2012 [59]	Japan	Losartan	NA	20	48 w	58.6 ± 7.27	24.8 ± 2.76	41/14	NA	148 ± 9.1	87.8 ± 9.0	Vascular ultrasonography
		Nisoldipine	10 mg	27	8 w				NA	139 ± 5.1	97.3 ± 6.6	
		Olmesartan	20 mg	28	8 w				NA	141 ± 6.3	98.7 ± 5.2	
		Carvedilol	12.5 mg	23		45.6 ± 2.8	27.6 (6.2)	16/7	NA	154.2 ± 4.0	94.9 ± 2.4	
Zepeda et al., 2012 [48]	Chile	Nebivolol	5 mg	21	12 w	44.9 ± 2.1	26.7 (4.7)	15/6	NA	151.2 ± 4.1	93.9 ± 2.5	Vascular ultrasonography
		Olmesartan	5 mg	42	8 w	54.9 ± 7.9	30.6 ± 3.8	19/23	NA	146 ± 5	78 ± 8	
		Olmesartan	5 mg	42	8 w	50.1 ± 9.4	30.4 ± 4.7	11/32	NA	148 ± 7	78 ± 9	
		Nebivolol	10 mg	43	8 w	69.2 ± 7	NA	NA	NA	150	90	
Sendur et al., 2014 [33]	Turkey	Losartan + HCTZ	50 mg + 12.5 mg	21	8 w				NA	141NA168)	(90NA98)	Vascular ultrasonography
		Placebo	NA	21	8 w				NA	149	90	
		Perindopril	4 mg	27	12 w	NA	NA	NA	NA	(140NA160)	(89NA92)	
		HCTZ	25 mg	32	12 w	NA	NA	NA	NA	147	89 (77–92)	
Takase et al., 2014 [60]	Japan	Benazepril	10 mg	14	12 w	57 (52–62)	29.5 (26.4–34.4)	5/9	NA	(128–158)	89 (77–92)	Vascular ultrasonography
		Losartan	50 mg	16	12 w	57 (53–63)	30.3 (27.4–33.2)	6/10	NA	143	81 (78–89)	
		Amlodipine	5 mg	48	3 m	49.12 ± 12.55	25.01 ± 2.72	22/26	NA	155.2 ± 11.7	95.9 ± 10.2	
		Amlodipine + atorvastatin	5 mg	52	3 m	48.41 ± 11.16	26.28 ± 3.29	25/27	NA	154.1 ± 10.3	96.3 ± 8.2	
Fonseca et al., 2015 [36]	Brazil	Irbesartan	150 mg	46	2 w	63.05 ± 10.13	24.03 ± 2.36	25/21	NA	135 ± 14	78 ± 7	Vascular ultrasonography
		Diltiazem	90 mg	51	2 w	62.32 ± 9.51	23.68 ± 2.71	28/23	NA	136 ± 11	81 ± 10	
		Irbesartan + diltiazem	150 mg + 90 mg	53	2 w	61.82 ± 8.96	24.64 ± 2.40	31/22	NA	139 ± 12	82 ± 10	
		Placebo	NA	34	30 d	41.2 ± 9.8	24.2 ± 1.34	18/16	NA	151.2 ± 5.5	96.0 ± 1.91	
Gismondi et al., 2015 [37]	Brazil	Allisartanisoproxil	240 mg	34	30 d	42.7 ± 9.2	24.0 ± 1.62	17/17	NA	151.1 ± 5.8	95.7 ± 2.2	Vascular ultrasonography
		Losartan	50 mg	16	12 w				NA	143	81 (78–89)	
		Amlodipine	5 mg	48	3 m	49.12 ± 12.55	25.01 ± 2.72	22/26	NA	155.2 ± 11.7	95.9 ± 10.2	
		Amlodipine + atorvastatin	5 mg	52	3 m	48.41 ± 11.16	26.28 ± 3.29	25/27	NA	154.1 ± 10.3	96.3 ± 8.2	
Zhao et al., 2017 [24]	China	Irbesartan	150 mg	46	2 w	63.05 ± 10.13	24.03 ± 2.36	25/21	NA	135 ± 14	78 ± 7	Vascular ultrasonography
		Diltiazem	90 mg	51	2 w	62.32 ± 9.51	23.68 ± 2.71	28/23	NA	136 ± 11	81 ± 10	
		Irbesartan + diltiazem	150 mg + 90 mg	53	2 w	61.82 ± 8.96	24.64 ± 2.40	31/22	NA	139 ± 12	82 ± 10	
		Placebo	NA	34	30 d	41.2 ± 9.8	24.2 ± 1.34	18/16	NA	151.2 ± 5.5	96.0 ± 1.91	
Zhou et al., 2017 [25]	China	Allisartanisoproxil	240 mg	34	30 d	42.7 ± 9.2	24.0 ± 1.62	17/17	NA	151.1 ± 5.8	95.7 ± 2.2	Vascular ultrasonography
		Losartan	50 mg	16	12 w				NA	143	81 (78–89)	
		Amlodipine	5 mg	48	3 m	49.12 ± 12.55	25.01 ± 2.72	22/26	NA	155.2 ± 11.7	95.9 ± 10.2	
		Amlodipine + atorvastatin	5 mg	52	3 m	48.41 ± 11.16	26.28 ± 3.29	25/27	NA	154.1 ± 10.3	96.3 ± 8.2	
Zhang et al., 2020 [26]	China	Irbesartan	150 mg	46	2 w	63.05 ± 10.13	24.03 ± 2.36	25/21	NA	135 ± 14	78 ± 7	Vascular ultrasonography
		Diltiazem	90 mg	51	2 w	62.32 ± 9.51	23.68 ± 2.71	28/23	NA	136 ± 11	81 ± 10	
		Irbesartan + diltiazem	150 mg + 90 mg	53	2 w	61.82 ± 8.96	24.64 ± 2.40	31/22	NA	139 ± 12	82 ± 10	
		Placebo	NA	34	30 d	41.2 ± 9.8	24.2 ± 1.34	18/16	NA	151.2 ± 5.5	96.0 ± 1.91	

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Akimi et al 2001	?	?	?	?	?	?	?
Aznaouridis et al 2007	?	?	?	?	?	?	?
Benndorf et al 2007	?	?	?	?	?	?	?
Buus et al 2007	?	?	?	?	?	?	?
Chung et al 2004	?	?	?	?	?	?	?
Fang et al 2002	?	?	?	?	?	?	?
Fonseca et al 2015	?	?	?	?	?	?	?
Fujimura et al 2012	?	?	?	?	?	?	?
Ghiadoni et al. 2001	?	?	?	?	?	?	?
Ghiadoni et al 2003	?	?	?	?	?	?	?
Ghiadoni et al 2007	?	?	?	?	?	?	?
Ghiadoni et al 2009	?	?	?	?	?	?	?
Gismondi et al 2015	?	?	?	?	?	?	?
Hefferman et al 2011	?	?	?	?	?	?	?
Hirooka et al 2008	?	?	?	?	?	?	?
Huang et al 2010	?	?	?	?	?	?	?
Iwatsubo et al 1997	?	?	?	?	?	?	?
Jung et al 2009	?	?	?	?	?	?	?
Kim et al 2009	?	?	?	?	?	?	?
Koh et al 2004	?	?	?	?	?	?	?
Koh et al 2007	?	?	?	?	?	?	?
Koh et al 2009	?	?	?	?	?	?	?
Koh et al 2010	?	?	?	?	?	?	?
Korkmaz et al 2008	?	?	?	?	?	?	?
Kosch et al 2008	?	?	?	?	?	?	?
Morimoto et al 2006	?	?	?	?	?	?	?
Morimoto et al 2007	?	?	?	?	?	?	?
Muiesan et al 1999	?	?	?	?	?	?	?
Muiesan et al 2011	?	?	?	?	?	?	?
Munakata et al 2003	?	?	?	?	?	?	?
Pasini et al 2007	?	?	?	?	?	?	?
Pasini et al 2008	?	?	?	?	?	?	?
Sekuri et al 2003	?	?	?	?	?	?	?
Sendur et al 2014	?	?	?	?	?	?	?
Simova et al 2009	?	?	?	?	?	?	?
Souza-Bardosa et al 2006	?	?	?	?	?	?	?
Sozen et al 2009	?	?	?	?	?	?	?
Takase et al 2014	?	?	?	?	?	?	?
Takiguchi et al 2011	?	?	?	?	?	?	?
Tezcan et al 2003	?	?	?	?	?	?	?
Wei et al 2012	?	?	?	?	?	?	?
Yamada et al 2008	?	?	?	?	?	?	?
Yamanari et al 2004	?	?	?	?	?	?	?
Yamanari et al 2009	?	?	?	?	?	?	?
Yavuz et al 2003	?	?	?	?	?	?	?
Zepeda et al 2012	?	?	?	?	?	?	?
Zhang et al 2020	?	?	?	?	?	?	?
Zhao et al 2017	?	?	?	?	?	?	?
Zhou et al 2017	?	?	?	?	?	?	?

FIGURE 2: Methodological quality summary: review authors' judgments about each methodological quality.

3.6. *Subgroup Analysis for FMD.* In the subgroup analysis for FMD, the combination of CCB and ARB followed by ACEI mono-therapy (SUCRA = 68.3%), exerted beneficial effects

in increasing FMD for treatment duration  $\leq 8$  weeks (SUCRA = 89.7%). For treatment duration  $> 8$  weeks, such significant differences were absent for combination of CCB and ARB treatment among the available studies. ARB mono-therapy had superior effects as compared to other antihypertensive drugs (SUCRA = 78.9%) (Figures 9 and 10). For patients aged  $\leq 55$  years, no significant differences due to the combination of CCB and ARB were observed. ACEI was significantly associated with an increase in FMD in comparison with other antihypertensive drugs (SUCRA = 78.9%). When compared with other antihypertensive drugs, the combination of CCB and ARB was associated with a significant increment in FMD in the participants aged  $> 55$  years included (SUCRA = 86.1%) (Figures 11 and 12).

3.7. *Publication Bias.* Potential publication biases in reporting effects of antihypertensive agents for the treatment of patients with hypertension were evaluated and shown as a funnel plot (Figure 13); not all studies were symmetrically distributed around the vertical line,  $X = 0$ , which indicated that there was evidence of small sample effect in the research network.

3.8. *Sensitivity Analysis.* Sensitivity analysis was performed according to random effects model to evaluate the stability and reliability of the combined results of the meta-analyses and assess whether the combined results were unduly affected by the results of a single study. This procedure was conducted using Stata. After eliminating the individual studies one by one, most of the combined effect sizes were relatively minor, which indicated that the results of this meta-analysis were relatively stable.

#### 4. Discussion

A total of 49 RCTs examining the effects of the most commonly prescribed antihypertension medications for improving endothelial function as measured by brachial FMD, were included in the present analysis. The pooled results showed that a combination of CCB and ARB, followed by ACEI (SUCRA = 74.2%) exerted synergistic effects in protecting the endothelial function (SUCRA = 89.0%) by enhancing the FMD. The network meta-analysis also showed that CCB played a better role in improving the BAD value (SUCRA = 90.6%). Our study provided the most current evidence on the comparative efficacy of antihypertensive medications, which have been previously in improving vascular function in RCTs. Furthermore, to the best of our knowledge, this is the first network meta-analysis that pools the results of studies that have tested the efficacies of antihypertension medications on protecting endothelial functions by increasing FMD.

FMD has been widely used for the assessment of endothelial function in humans owing to its non-invasive nature [61]. A recent meta-analysis concludes that a significantly lower risk (8–13%) of CV events per percentage point increase in brachial artery FMD occurs [62]. Our




FIGURE 3: Methodological quality graph: reviewer author's judgments about each methodological quality item presented as percentage across all included studies.






FIGURE 4: The construction of the network. (a) Flow-mediated dilation, (b) brachial artery diameter) ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.



network meta-analysis showed that the combination of CCB and ARB significantly increased FMD by 4.01% and 3.32% as compared to placebo and CCB, respectively. Results in this network meta-analysis are consistent with those reported in previous meta-analyses of RCTs. Miroslav et al [63] found that CCB was efficient and effective for the improvement of the FMD parameters. Michał et al [64] indicated that beta-blockers can significantly improve the endothelial function as compared to placebo. However, these meta-analyses found no statistical differences among the efficacies of the antihypertensive medications. Yousef et al [6] report that ACEI mono-therapy is the most effective treatment regime for improving FMD as compared to CCB and beta-blockers. Jian-Dong Chen et al. [7] also found no significant difference among the different classes of antihypertensive drugs on FMD. Our findings further support the evidence for ACEI monotherapy among the antihypertensive medications, as the most effective treatment for improving FMD. Our finding was in contrast with a previous study, and indicated that a combination of CCB and ARB was the most effective treatment for improving FMD. Mechanistic insights into the effects of antihypertensive medications on FMD have not been fully elucidated, however plausible explanations have

been proposed. Oxidative stress [65] and inflammation [66] are the main causes of hypertension-related endothelial dysfunction, as both significantly reduce the bioavailability of nitric oxide [67]. Beyond this, elevated blood pressure may damage endothelial cells and, cause their irreversible damage [68]. ARB can promote the release of nitric oxide and accelerate the effect of acetylcholine on endothelium-dependent vasodilation [69]. These compounds can reverse endothelial dysfunction spontaneously hypertensive rats [70] and ameliorate FMD in patients with hypertension. CCB not only effectively reduces blood pressure but also increases the production of endothelial nitric oxide synthase, thereby improving nitric oxide bioavailability and endothelial function [7]. The results of some clinical trials show that CCB is frequently combined with ARB and improves endothelial dysfunction, thus it can be reasonably concluded that the improvement of endothelial function is significantly dependent upon the synergistic or additive pleiotropic actions of the aforementioned drugs. ARB combined with CCB is recommended in many guidelines for slowing down the progression of hypertension [71]. In experimental conditions, endothelium-dependent vasodilation was shown to benefit from the synergistic effect and complementary





(a)



(b)

FIGURE 5: Results of test for inconsistency. ((a) flow-mediated dilation, (b) brachial artery diameter). A, placebo; B, CCB (calcium channel blockers); C, ACEI (angiotensin-converting enzyme inhibitors); D, ARB (angiotensin receptor blocker); E,  $\beta$ -blocker; F, diuretic; G, CCB +  $\beta$ -blocker; H, ACEI + ARB; I, ARB + CCB; G, ACEI + CCB.




FIGURE 6: Results of test for inconsistency. (a) Flow-mediated dilation, (b) brachial artery diameter) ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.

mechanism of the combination of CCB and ARB causes the amelioration of both oxidative stress and the impaired Akt/eNOS pathway, along with inhibition of ERK activation [72]. Evidence from clinical and experimental data also supports the use of ARB combination with CCB, which may provide superior vascular protection through an enhanced anti-

inflammatory mechanism [25]. Simultaneously, the network meta-analysis also indicated the beneficial effects of the combination of ACEI and ARB on FMD (SUCRA = 78.2). However, the combined effect of the two drugs on FMD was not statistically significant as compared to the effect of either of these drugs individually. ACEI could also dramatically

TABLE 2: Inconsistency test between direct and indirect treatment comparisons in mixed treatment comparison in FMD.

Side	Direct		Indirect		Difference		$p >  z $
	Coefficient	SE	Coefficient	SE	Coefficient	SE	
Placebo CCB	0.720	1.03	0.710	0.750	0.010	1.275	0.994
Placebo ACEI	8.700	1.580	1.641	0.595	7.059	1.688	0.000
Placebo ARB	0.790	1.053	2.820	0.700	-2.030	1.264	0.108
Placebo diuretic	0.840	1.133	2.081	0.729	-1.241	1.347	0.357
CCB ACEI	1.801	0.619	1.874	0.423	-0.073	0.748	0.922
CCB ARB	1.574	0.398	1.449	0.432	-0.073	0.7475	0.922
CCB $\beta$ -blocker	1.077	0.7567	1.699	0.470	-0.622	0.890	0.485
CCB diuretic	1.039	0.477	0.990	0.474	0.489	0.672	0.942
CCB ARB + CCB	4.900	1.994	1.404	2.191	3.496	2.963	0.238
CCB ACEI + CCB	0.600	1.164	-1.389	173.981	1.989	173.985	0.991
ACEI ARB	0.055	0.476	-0.655	0.426	0.710	0.639	0.267
ACEI $\beta$ -blocker	-0.219	0.533	-0.440	0.549	0.221	0.764	0.773
ACEI diuretic	-1.234	0.881	-1.437	0.520	0.203	1.025	0.843
ACEI CCB + $\beta$ -blocker	-2.5	1.700	-4.990	187.339	2.491	187.352	0.989
ACEI ACEI + ARB	0.605	0.819	-0.213	0.939	0.818	1.246	0.511
ARB $\beta$ -blocker	-0.058	0.641	0.046	0.483	-0.105	0.803	0.896
ARB diuretic	-0.118	0.524	-0.766	0.436	0.647	0.681	0.342
ARB ACEI + ARB	0.580	1.126	0.585	0.784	-0.006	1.373	0.997
ARB ARB + CCB	-0.80	2.172	3.414	2.015	-3.494	2.963	0.238
$\beta$ -Blocker diuretic	-1.170	1.019	-0.364	0.480	-0.806	1.126	0.474
$\beta$ -Blocker ACEI + diuretic	0.400	1.148	-4.524	112.722	4.924	112.729	0.965

SE, standard error; ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.

TABLE 3: Inconsistency test between direct and indirect treatment comparisons in mixed treatment comparison in BAD.

Side	Direct		Indirect		Difference		$P >  z $
	Coefficient	SE	Coefficient	SE	Coefficient	SE	
CCB ACEI	-0.069	0.151	-0.130	0.122	0.061	0.195	0.753
CCB ARB	-0.286	0.086	-0.128	0.150	-0.158	0.172	0.359
CCB $\beta$ -blocker	-1.69	0.214	-0.211	0.106	0.211	0.239	0.377
ACEI ARB	0.018	0.135	-0.251	0.112	0.269	0.175	0.125
ACEI $\beta$ -blocker	-0.148	0.109	0.070	0.137	-0.218	0.175	0.212
ARB $\beta$ -blocker	0.114	0.103	0.016	0.136	0.097	0.172	0.573

enhance FMD (SUCRA = 74.2) by inhibiting the angiotensin-converting enzyme, thereby suppressing the angiotensin II activity and increasing bradykinin production. Baseline BAD is an important determinant of FMD of the brachial artery, where in the FMD is calculated as a relative percentage change in the baseline BAD during reactive hyperemia. CCB lowers blood pressure by inhibiting the L-type calcium channel involved in the influx of calcium ions, leading to vascular smooth muscle relaxation and consequent peripheral vasodilation [73].

Taken together, ARB combined with CCB may be more beneficial for alleviating endothelial dysfunction in patients with hypertension. As hypertension-associated mechanisms differ among the patients, the effectiveness of anti-hypertension medications varies among individual patients, thereby offering reasonable effects of clinical therapy. The purpose of this network meta-analysis was to identify the most effective antihypertensive drugs for increasing FMD in patients suffering from hypertension. The advantage of network meta-analysis lies in that, the indirect comparisons among various drugs used in clinical practice, exerting the

same efficacies based on pairwise head-to-head direct randomized tests and ranking in order of the treatments to identify the superior ones among them, which helps in optimizing the therapeutic strategies. Therefore, it overcomes the shortcomings of conventional meta-analysis based on pairwise head-to-head direct comparison. However, this study also has some limitations. First, the network meta-analysis in this study may be limited by the selective reporting biases and small sample sizes. Second, the findings should be considered with caution, owing to the possibility of overestimation of the therapeutic effect, as the negative results have not been published. Third, only the articles published in English were included in this network meta-analysis, which may cause selection bias. Finally, a possibility of inaccuracy in the information provided in published articles and online clinical research reports exists. In addition, most of the studies included were single-center studies without any specific description of randomization and blinding, which might bias the accuracy of the findings to uncertain extent. In order to increase the power of this meta-analysis, both RCTs were included in this network






FIGURE 7: Absolute mean (95% credible interval, CRI) difference. (a) Flow-mediated dilation, (b) brachial artery diameter). ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.

meta-analysis. Therefore, it is necessary to design rigorous large-sample, multicenter, RCTs to further study the effectiveness of antihypertensive drugs on FMD in patients with hypertension, and include experimental data to support the characteristics of various therapeutic drugs.

In conclusion, the meta-analysis presented here indicated that ARB combined with CCB was superior in improving the endothelial function measured as FMD status. ACEI mono-therapy was the most effective treatment for increasing FMD among all the antihypertension




(a)




(b)

FIGURE 8: Mean ranking plots. (a) Flow-mediated dilation, (b) brachial artery diameter). ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.




(a)




(b)

FIGURE 9: Subgroup analysis of forest plots for the assessment of duration treatments in FMD. (a) Duration treatments ≤ 8 weeks, (b) duration treatments > 8 weeks). ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.




(a)




(b)

FIGURE 10: Subgroup analysis of cumulative ranking probability plot for the assessment of duration treatments in FMD. (a) Duration treatments  $\leq 8$  weeks, (b) duration treatments  $> 8$  weeks) ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.



(a)



(b)

FIGURE 11: Subgroup analysis of forest plots for the assessment of age in FMD. (a) Age ≤55 years, (b) aged >55 years). ACEI: angiotensinconverting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.






FIGURE 12: Subgroup analysis of cumulative ranking probability plot for the assessment of duration treatments in FMD. (a) Age  $\leq 55$  years, (b) aged  $> 55$  years). ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blockers.

medications. There was no significant difference between mono-therapeutic antihypertensive drugs.

**Appendix**

Search strategy: we search for all relevant articles published in English until November 1, 2020, in PubMed, Embase, and the Cochrane Library. We conduct the following searches.

PubMed search strategy: ((angiotensin-converting enzyme inhibitors OR captopril OR zofenopril OR enalapril OR ramipril OR quinapril OR perindopril OR lisinopril OR benzazepines OR fosinopril OR alacepril OR cilazapril OR delapril OR imidapril OR moexipril OR rentiapril OR spirapril OR temocapril OR trandolapril) OR (angiotensin receptor antagonists OR azilsartan OR candesartan OR eprosartan OR irbesartan OR losartan OR olmesartan OR tasosartan OR telmisartan OR valsartan) OR (calcium




FIGURE 13: Funnel plot. ((a) flow-mediated dilation, (b) brachial artery diameter) A, placebo; B, CCB (calcium channel blockers); C, ACEI (angiotensin-converting enzyme inhibitors); D, ARB (angiotensin receptor blocker); E,  $\beta$ -blocker; F, diuretic; G, CCB +  $\beta$ -blocker; H, ACEI + ARB; I, ARB + CCB; J, ACEI + CCB.

channel blockers OR amlodipine OR aranidipine OR azel-  
nidipine OR barnidipine OR benidipine OR cilnidipine OR  
clevidipine OR darodipine OR efonidipine OR felodipine  
OR isradipine OR lacidipine OR manidipine OR lercani-  
dipine OR mepirodipine OR nicardipine OR nifedipine OR  
niludipin OR nilvadipine OR nimodipine OR nisoldipine  
OR nitrendipine OR oxodipine OR pranidipine OR ryodi-  
pine OR anipamil OR devapamil OR emopamil OR falipamil  
OR gallopamil OR verapamil OR clentiazem OR diltiazem  
OR dihydropyridines) OR (adrenergic beta-antagonists OR  
alprenolol OR bopindolol OR bupranolol OR carteolol OR

cloranolol OR mepindolol OR nadolol OR oxprenolol OR  
penbutolol OR pindolol OR propranolol OR sotalol OR  
tertanolol OR timolol OR betaxolol OR acebutolol OR  
bevantolol OR bisoprolol OR epanolol OR celiprolol OR  
esmolol OR metoprolol OR practolol OR atenolol OR  
talinolol OR carvedilol OR labetalol OR nebivolol OR  
butoxamine) OR (acetazolamide OR diuretics OR furose-  
mide OR bumetanide OR torasemide OR ethacrynic acid OR  
thiazides OR hydrochlorothiazide bendroflumethiazide OR  
hydroflumethiazide OR chlorothiazide OR polythiazide OR  
trichlormethiazide OR cyclopenthiazide OR

methylothiazide OR cyclothiazide OR mebutizide OR quinethazone OR clopamide OR chlorthalidone OR mefruside OR clofexamide OR metolazone OR meticrane OR xipamide OR indapamide OR clorexolone OR fenquize OR amiloride OR triamterene OR benzamil OR spironolactone OR eplerenone OR canrenoate potassium OR canrenone) OR (adrenergic alpha-antagonists OR prazosin OR indoramin OR trimazosin OR doxazosin OR urapidil OR alfuzosin OR silodosin OR tamsulosin OR terazosin) OR (antihypertensive agents) AND (hypertension OR high blood pressure) AND (flow-mediated vasodilation OR flow mediated dilatation OR nitroglycerine-induced vasodilation OR Vascular Function Tests OR endothelial function)

Cochrane Library search strategy: (1) Angiotensin-Converting Enzyme Inhibitors OR Captopril OR Zofenopril OR Enalapril OR Ramipril OR Quinapril OR Perindopril OR Lisinopril OR Benzazepines OR Fosinopril OR Alacepril OR Cilazapril OR Delapril OR Imidapril OR Rentiapril OR Spirapril OR Temocapril OR Trandolapril; (2) Angiotensin Receptor Antagonists OR Azilsartan OR Candesartan OR Eprosartan OR Irbesartan OR Losartan OR Olmesartan OR Tasosartan OR Telmisartan OR Valsartan; (3) Calcium Channel Blockers OR Amlodipine OR Arandipine OR Azelnidipine OR Barnidipine OR Benidipine OR Cilnidipine OR Clevidipine OR Darodipine OR Efonidipine OR Felodipine OR Isradipine OR Lacidipine OR Manidipine OR Lercanidipine OR Mepirodipine OR Nicardipine OR Nifedipine OR Niludipin OR Nilvadipine OR Nimodipine OR Nisoldipine OR Nitrendipine OR Oxodipine OR Prandipine OR Ryodipine OR Anipamil OR Devapamil OR Emopamil OR Falipamil OR Gallopamil OR Verapamil OR Clentiazem OR Diltiazem OR Dihydropyridines; (4) Adrenergic beta-Antagonists OR Alprenolol OR Bopindolol OR Bupranolol OR Carteolol OR Cloranolol OR Mepindolol OR Nadolol OR Oxprenolol OR Penbutolol OR Pindolol OR Propranolol OR Sotalol OR Tertatolol OR Timolol OR Betaxolol OR Acebutolol OR Bevantolol OR Bisoprolol OR Epanolol OR Celiprolol OR Esmolol OR Metoprolol OR Practolol OR Atenolol OR Talinolol OR Carvedilol OR Labetalol OR Nebivolol OR Butoxamine; (5) Acetazolamide OR Diuretics OR Furosemide OR Bumetanide OR Torasemide OR Ethacrynic Acid OR Thiazides OR Hydrochlorothiazide OR Bendroflumethiazide OR Hydroflumethiazide OR Chlorothiazide OR Polythiazide OR Trichlormethiazide OR Cyclopenthiiazide OR Methylothiazide OR Cyclothiazide OR Mebutizide OR Quinethazone OR Clopamide OR Chlorthalidone OR Mefruside OR Clofenamide OR Metolazone OR Meticrane OR Xipamide OR Indapamide OR Clorexolone OR Fenquize OR Amiloride OR Triamterene OR Benzamil OR Spironolactone OR Eplerenone OR Canrenoate Potassium OR Canrenone; (6) Adrenergic alpha-Antagonists OR Prazosin OR Indoramin OR Trimazosin OR Doxazosin OR Urapidil OR Alfuzosin OR Silodosin OR Tamsulosin OR Terazosin; (7) Anti-hypertensive Agents; (8) (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7); (9) flow-mediated vasodilation OR flow mediated dilatation OR nitroglycerine-induced vasodilation OR Vascular Function Tests OR endothelial function; (10)

hypertension OR high blood pressure; (11) (#8 AND #9 AND #10).

Embase search strategy: (1) 'Angiotensin-Converting Enzyme Inhibitors' OR 'Captopril' OR 'Zofenopril' OR 'Enalapril' OR 'Ramipril' OR 'Quinapril' OR 'Perindopril' OR 'Lisinopril' OR 'Benzazepines' OR 'Fosinopril' OR 'Alacepril' OR 'Cilazapril' OR 'Delapril' OR 'Imidapril' OR 'Moexipril' OR 'Rentiapril' OR 'Spirapril' OR 'Temocapril' OR 'Trandolapril'; (2) 'Angiotensin Receptor Antagonists' OR 'Azilsartan' OR 'Candesartan' OR 'Eprosartan' OR 'Irbesartan' OR 'Losartan' OR 'Olmesartan' OR 'Tasosartan' OR 'Telmisartan' OR 'Valsartan'; (3) 'Calcium Channel Blockers' OR 'Amlodipine' OR 'Arandipine' OR 'Azelnidipine' OR 'Barnidipine' OR 'Benidipine' OR 'Cilnidipine' OR 'Clevidipine' OR 'Darodipine' OR 'Efonidipine' OR 'Felodipine' OR 'Isradipine' OR 'Lacidipine' OR 'Manidipine' OR 'Lercanidipine' OR 'Mepirodipine' OR 'Nicardipine' OR 'Nifedipine' OR 'Niludipin' OR 'Nilvadipine' OR 'Nimodipine' OR 'Nisoldipine' OR 'Nitrendipine' OR 'Oxodipine' OR 'Prandipine' OR 'Ryodipine' OR 'Anipamil' OR 'Devapamil' OR 'Emopamil' OR 'Falipamil' OR 'Gallopamil' OR 'Verapamil' OR 'Clentiazem' OR 'Diltiazem' OR 'Dihydropyridines'; (4) 'Adrenergic beta-Antagonists' OR 'Alprenolol' OR 'Bopindolol' OR 'Bupranolol' OR 'Carteolol' OR 'Cloranolol' OR 'Mepindolol' OR 'Nadolol' OR 'Oxprenolol' OR 'Penbutolol' OR 'Pindolol' OR 'Propranolol' OR 'Sotalol' OR 'Tertatolol' OR 'Timolol' OR 'Betaxolol' OR 'Acebutolol' OR 'Bevantolol' OR 'Bisoprolol' OR 'Epanolol' OR 'Celiprolol' OR 'Esmolol' OR 'Metoprolol' OR 'Practolol' OR 'Atenolol' OR 'Talinolol' OR 'Carvedilol' OR 'Labetalol' OR 'Nebivolol' OR 'Butoxamine'; (5) 'Acetazolamide' OR 'Diuretics' OR 'Furosemide' OR 'Bumetanide' OR 'Torasemide' OR 'Ethacrynic Acid' OR 'Thiazides' OR 'Hydrochlorothiazide' OR 'Bendroflumethiazide' OR 'Hydroflumethiazide' OR 'Chlorothiazide' OR 'Polythiazide' OR 'Trichlormethiazide' OR 'Cyclopenthiiazide' OR 'Methylothiazide' OR 'Cyclothiazide' OR 'Mebutizide' OR 'Quinethazone' OR 'Clopamide' OR 'Chlorthalidone' OR 'Mefruside' OR 'Clofenamide' OR 'Metolazone' OR 'Meticrane' OR 'Xipamide' OR 'Indapamide' OR 'Clorexolone' OR 'Fenquize' OR 'Amiloride' OR 'Triamterene' OR 'Benzamil' OR 'Spironolactone' OR 'Eplerenone' OR 'Canrenoate Potassium' OR 'Canrenone'; (6) 'Adrenergic alpha-Antagonists' OR 'Prazosin' OR 'Indoramin' OR 'Trimazosin' OR 'Doxazosin' OR 'Urapidil' OR 'Alfuzosin' OR 'Silodosin' OR 'Tamsulosin' OR 'Terazosin'; (7) 'Anti-hypertensive Agents'; (8) (1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7); (9) 'flow-mediated vasodilation' OR 'flow mediated dilatation' OR 'nitroglycerine-induced vasodilation' OR 'Vascular Function Tests' OR 'endothelial function'; (10) 'hypertension' OR 'high blood pressure'; (11) (8 AND 9 AND 10). <https://downloads.hindawi.com/journals/ijhy/2022/2432567.f1.docx>

## Data Availability

All data generated or analyzed are included in this article.

## Conflicts of Interest

The authors declare no conflicts of interest.

## Authors' Contributions

The contributions of Hong Ding and Shu Liu in this study are consistent.

## Acknowledgments

This work was supported by National Natural Science Foundation of China (NSFC 82060080), Gansu science and Technology Department Project (20YF3WA016), Gansu Youth Science and Technology Fund Program (2021-0406-JCC-0595), and Gansu Heart Rehabilitation Engineering Research Center (CRQI-C00535).

## References

- [1] "Key points of report on cardiovascular health and diseases in China 2020," *Chinese Journal of Cardiovascular Research*, vol. 19, pp. 582–590, 2020.
- [2] B. Williams, G. Mancia, W. Spiering et al., "ESC/ESH Guidelines for the management of arterial hypertension," *European Heart Journal*, vol. 39, pp. 3021–3104, 2018.
- [3] P. Poredos, A. Visnovic Poredos, and I. Gregoric, "Endothelial dysfunction and its clinical implications," *Angiology*, vol. 72, no. 7, pp. 604–615, Article ID 3319720987752, 2021.
- [4] O. A. Ekun, F. Daniel, P. Adebola et al., "Assessment of plasma sodium to potassium ratio, renal function, markers of oxidative stress, inflammation, and endothelial dysfunction in Nigerian hypertensive patients," *International Journal of Hypertension*, vol. 2020, Article ID 6365947, 8 pages, 2020.
- [5] T. Herbrand, H. V. Coester, R. Sansone et al., "Improving the assessment of flow-mediated dilation through detection of peak time in healthy subjects and subjects with type 2 diabetes," *Angiology*, vol. 72, no. 5, pp. 434–441, Article ID 3319720984884, 2020.
- [6] Y. Shahin, J. A. Khan, N. Samuel, and I. Chetter, "Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials," *Atherosclerosis*, vol. 216, no. 1, pp. 7–16, 2011.
- [7] J.-D. Chen, M. Liu, X.-h. Chen, and Z.-J. Yang, "Effect of Angiotensin receptor blockers on flow-mediated vasodilation: a meta-analysis of randomized controlled trials," *Cardiology*, vol. 131, no. 2, pp. 69–79, 2015.
- [8] D. Moher, L. Shamseer, L. Shamseer et al., "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement," *Systematic Reviews*, vol. 4, no. 1, p. 1, 2015.
- [9] L. Shamseer, D. Moher, M. Clarke et al., "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation," *BMJ*, vol. 349, no. 1, Article ID g7647, 2015.
- [10] A. Chaimani, D. M. Caldwell, T. Li, J. P. T. Higgins, and G. Salanti, "Additional considerations are required when preparing a protocol for a systematic review with multiple interventions," *Journal of Clinical Epidemiology*, vol. 83, pp. 65–74, 2017.
- [11] S. Shim, B.-H. Yoon, I.-S. Shin, and J.-M. Bae, "Network meta-analysis: application and practice using Stata," *Epidemiology and Health*, vol. 39, Article ID e2017047, 2017.
- [12] M. L. Muiesan, M. Salvetti, C. Monteduro et al., "Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension," *Hypertension*, vol. 33, pp. 575–580, 1999.
- [13] L. Ghiadoni, Y. Huang, A. Magagna, S. Buralli, S. Taddei, and A. Salvetti, "Effect of acute blood pressure reduction on endothelial function in the brachial artery of patients with essential hypertension," *Journal of Hypertension*, vol. 19, pp. 547–551, 2001.
- [14] L. Ghiadoni, A. Magagna, D. Versari et al., "Different effect of antihypertensive drugs on conduit artery endothelial function," *Hypertension*, vol. 41, no. 6, pp. 1281–1286, 2003.
- [15] L. Ghiadoni, D. Versari, A. Magagna et al., "Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients," *Journal of Hypertension*, vol. 25, pp. 361–366, 2007.
- [16] A. F. Pasini, U. Garbin, M. C. Nava et al., "Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients," *American Journal of Hypertension*, vol. 20, pp. 443–450, 2007.
- [17] A. F. Pasini, U. Garbin, C. Stranieri et al., "Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients," *American Journal of Hypertension*, vol. 21, no. 11, pp. 1251–1257, 2008.
- [18] L. Ghiadoni, A. Magagna, I. Kardasz, S. Taddei, and A. Salvetti, "Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients," *American Journal of Hypertension*, vol. 22, pp. 506–512, 2009.
- [19] M. L. Muiesan, M. Salvetti, E. Belotti et al., "Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients," *Blood Pressure*, vol. 20, pp. 244–251, 2011.
- [20] R. A. Benndorf, D. Appel, R. Maas, E. Schwedhelm, U. O. Wenzel, and R. H. Böger, "Telmisartan improves endothelial function in patients with essential hypertension," *Journal of Cardiovascular Pharmacology*, vol. 50, pp. 367–71, 2007.
- [21] L. Fang, F. Zheng, T. Qingyin, Z. Ming, and Y. Hu, "Effect of ramipril on endothelial dysfunction in patients with essential hypertension," *Clinical Drug Investigation*, vol. 22, pp. 449–453, 2002.
- [22] X. Huang, Z. Yun, Z. Mei, and S. Yu, "Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy," *Blood Pressure*, vol. 19, no. 1, pp. 40–47, 2010.
- [23] D. Wei, W. Y. He, and Q. Z. Lv, "Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients," *CNS Neuroscience & Therapeutics*, vol. 18, pp. 400–405, 2012.
- [24] X.-K. Zhao, F. Ming-Xia, Q. Ai-Ling, L. Kai, Z. Xu, and Y.-D. Li, "Amlodipine/atorvastatin has an effect on vascular function and normal lipid levels," *Biomedical Research*, vol. 28, pp. 3821–3825, 2017.
- [25] T. Zhou, X. Huang, X. Cai, and L. Xie, "Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives," *Clinical and Experimental Hypertension*, vol. 39, no. 7, pp. 612–618, 2017.
- [26] G. Zhang, Y. Fan, Y. Qiu et al., "Allisartan isoproxil improves endothelial function and vascular damage in patients with essential hypertension: a single-center, open-label,

- randomized controlled trial," *Advances in Therapy*, vol. 37, no. 8, pp. 3551–3561, 2020.
- [27] C. Sekuri, O. Bayturan, H. Gocer, T. Tavli, and U. K. Tezcan, "Effects of low-dose combination therapy with an angiotensin-converting enzyme inhibitor and a diuretic on flow-mediated vasodilation in hypertensive patients: a 6-month, single-center study," *Current Therapeutic Research*, vol. 64, no. 9, pp. 715–724, 2003.
- [28] H. Tezcan, D. Yavuz, A. Toprak et al., "Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients," *Journal of the Renin-Angiotensin-Aldosterone System: Journal of the Renin-Angiotensin-Aldosterone System*, vol. 4, pp. 119–123, 2003.
- [29] D. Yavuz, M. Koç, A. Toprak et al., "Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 4, no. 3, pp. 197–203, 2003.
- [30] M. Kosch, A. Levers, D. Lang et al., "A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension," *Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association*, vol. 23, pp. 2280–2285, 2008.
- [31] H. Korkmaz, I. Karaca, M. Koç, O. Önalın, M. Yılmaz, and M. N. Bilen, "Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension," *Endothelium*, vol. 15, no. 3, pp. 149–155, 2008.
- [32] N. B. Lemos, J. K. Angeli, T. d. O. Faria et al., "Low mercury concentration produces vasoconstriction, decreases nitric oxide bioavailability and increases oxidative stress in rat conductance artery," *PLoS One*, vol. 7, no. 11, Article ID e49005, 2012.
- [33] M. A. Sendur, G. S. Güven, H. Yorgun et al., "Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study," *The Anatolian Journal of Cardiology*, vol. 14, pp. 363–369, 2014.
- [34] N. A. Chung, D. G. Beevers, and G. Lip, "Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension," *Blood Pressure*, vol. 13, pp. 183–189, 2004.
- [35] L. A. Souza-Barbosa, S. E. Ferreira-Melo, S. Ubaid-Girioli, E. A. Nogueira, Y.-T. Juan Carlos, and M. Heitor Jr., "Endothelial vascular function in hypertensive patients after renin-angiotensin system blockade," *Journal of Clinical Hypertension*, vol. 8, pp. 803–809, 2006.
- [36] H. A. R. Fonseca, F. A. Fonseca, L. C. Lins et al., "Antihypertensive therapy increases natural immunity response in hypertensive patients," *Life Sciences*, vol. 143, pp. 124–130, 2015.
- [37] R. A. Gismondi, W. Oigman, R. Bedirian, C. R. Pozzobon, M. C. Ladeira, and M. F. Neves, "Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial," *Journal of the Renin-Angiotensin-Aldosterone System: Journal of the Renin-Angiotensin-Aldosterone System*, vol. 16, pp. 967–974, 2015.
- [38] K. A. Aznaouridis, K. S. Stamatelopoulos, E. N. Karatzis, A. D. Protogerou, C. M. Papamichael, and J. P. Lekakis, "Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients," *Journal of Human Hypertension*, vol. 21, pp. 654–663, 2007.
- [39] N. H. Buus, C. G. Jørgensen, M. J. Mulvany, and K. E. Sørensen, "Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade," *Blood Pressure*, vol. 16, pp. 106–113, 2007.
- [40] K. K. Koh, M. J. Quon, Y. Lee et al., "Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients," *European Heart Journal*, vol. 28, pp. 1440–1447, 2007.
- [41] A. D. Jung, W. Kim, S. H. Park et al., "The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension," *Korean Circulation Journal*, vol. 39, no. 5, pp. 180–184, 2009.
- [42] K. H. Kim, M. H. Jeong, S. H. Cho et al., "Clinical effects of calcium channel blocker and Angiotensin converting enzyme inhibitor on endothelial function and arterial stiffness in patients with angina pectoris," *Journal of Korean Medical Science*, vol. 24, pp. 223–231, 2009.
- [43] K. K. Koh, S. H. Han, J. Y. Ahn, W. J. Chung, Y. Lee, and E. K. Shin, "Amlodipine improves endothelial function and metabolic parameters in patients with hypertension," *International Journal of Cardiology*, vol. 133, pp. 23–31, 2009.
- [44] K. K. Koh, M. J. Quon, S. H. Han et al., "Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs," *International Journal of Cardiology*, vol. 140, no. 1, pp. 73–81, 2010.
- [45] K. K. Koh, M. J. Quon, S. H. Han et al., "Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients," *Circulation*, vol. 110, no. 24, pp. 3687–3692, 2004.
- [46] I. I. Simova, R. R. Todorova-Konstantinova, and S. V. Denchev, "Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients," *Experimental and Clinical Cardiology*, vol. 14, pp. 45–49, 2009.
- [47] K. S. Heffernan, R. Suryadevara, E. A. Patvardhan, P. Mooney, R. H. Karas, and J. T. Kuvın, "Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension," *Clinical Cardiology*, vol. 34, pp. 39–44, 2011.
- [48] R. J. Zepeda, R. Castillo, R. Rodrigo et al., "Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension," *Basic and Clinical Pharmacology and Toxicology*, vol. 111, pp. 309–316, 2012.
- [49] H. Yamanari, K. Nakamura, M. Kakishita, and T. Ohe, "Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors," *Clinical Cardiology*, vol. 27, no. 9, pp. 523–527, 2004.
- [50] H. Iwatsubo, M. Nagano, T. Sakai et al., "Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension," *Hypertension*, vol. 29, no. 1, pp. 286–290, 1997.
- [51] J. Stiles, C. Amaya, R. Pham et al., "Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis," *Experimental and Therapeutic Medicine*, vol. 4, no. 4, pp. 594–604, 2012.
- [52] M. Munakata, A. Aihara, T. Nunokawa et al., "The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension--comparison with calcium channel blockers," *Clinical and Experimental Hypertension*, vol. 25, no. 3, pp. 169–181, 2003.

- [53] S. Morimoto, Y. Yano, K. Maki, and K. Sawada, "Renal and vascular protective effects of telmisartan in patients with essential hypertension," *Hypertension Research: Official Journal of the Japanese Society of Hypertension*, vol. 29, pp. 567–572, 2006.
- [54] S. Morimoto, Y. Yano, K. Maki, and T. Iwasaka, "Renal and vascular protective effects of cilnidipine in patients with essential hypertension," *Journal of Hypertension*, vol. 25, pp. 2178–2183, 2007.
- [55] Y. Hirooka, Y. Kimura, Y. Sagara, K. Ito, and K. Sunagawa, "Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension," *Clinical and Experimental Hypertension*, vol. 30, no. 3-4, pp. 267–276, 2008.
- [56] J. Yamada, H. Tomiyama, C. Matsumoto, M. Yoshida, K. Shiina, and A. Yamashina, "Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions," *Journal of Cardiology*, vol. 51, pp. 114–1120, 2008.
- [57] H. Yamanari, K. Nakamura, D. Miura, Y. Shuichi, and T. Ohe, "Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress," *Clinical and Experimental Hypertension (New York, NY: 1993)*, vol. 31, pp. 585–594, 2009.
- [58] S. Takiguchi, M. Ayaori, H. Uto-Kondo et al., "Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase," *Hypertension Research*, vol. 34, no. 6, pp. 686–692, 2011.
- [59] N. Fujimura, K. Noma, T. Hata et al., "Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension," *Clinical Pharmacology & Therapeutics*, vol. 91, pp. 289–297, 2012.
- [60] B. Takase and M. Nagata, "Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study," *Anadolu Kardiyoloji Dergisi : AKD = the Anatolian journal of cardiology*, vol. 14, pp. 685–691, 2014.
- [61] J. C. Tremblay and K. E. Pyke, "Flow-mediated dilation stimulated by sustained increases in shear stress: a useful tool for assessing endothelial function in humans?" *American Journal of Physiology - Heart and Circulatory Physiology*, vol. 314, pp. H508–H520, 2018.
- [62] R. T. Ras, M. T. Streppel, R. Draijer, and P. L. Zock, "Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis," *International Journal of Cardiology*, vol. 168, no. 1, pp. 344–351, 2013.
- [63] M. Radenković, M. Stojanović, and M. Prostran, "Calcium channel blockers in restoration of endothelial function: systematic review and meta-analysis of randomized controlled trials," *Current Medicinal Chemistry*, vol. 26, pp. 5579–5595, 2019.
- [64] M. Peller, K. Ozierański, P. Balsam, M. Grabowski, K. J. Filipiak, and G. Opolski, "Influence of beta-blockers on endothelial function: a meta-analysis of randomized controlled trials," *Cardiology Journal*, vol. 22, no. 6, pp. 708–716, 2015.
- [65] L. Locatelli, G. Fedele, S. Castiglioni, and J. A. Maier, "Magnesium deficiency induces lipid accumulation in vascular endothelial cells via oxidative stress-the potential contribution of EDF-1 and PPAR $\gamma$ ," *International Journal of Molecular Sciences*, vol. 22, no. 3, p. 1050, 2021.
- [66] M. Wang, C. E. Murdoch, A. C. Brewer et al., "Endothelial NADPH Oxidase 4 Protects against Angiotensin II-Induced Cardiac Fibrosis and Inflammation," *ESC Heart Failure*, vol. 8, no. 2, pp. 1427–1437, 2021.
- [67] K. Kakabadze, I. Megreladze, N. Khvichia et al., "Some aspects of role of nitric oxide in the mechanisms of hypertension (experimental study)," *Cardiology Research*, vol. 12, no. 1, pp. 16–24, 2021.
- [68] D. Konukoglu and H. Uzun, "Endothelial dysfunction and hypertension," *Advances in Experimental Medicine and Biology*, vol. 956, pp. 511–540, 2017.
- [69] D.-R. Chen, H. Jiang, J. Chen, C.-C. Ruan, W.-Q. Han, and P.-J. Gao, "Involvement of angiotensin II type 1 receptor and calcium channel in vascular remodeling and endothelial dysfunction in rats with pressure overload," *Current Medical Science*, vol. 40, no. 2, pp. 320–326, 2020.
- [70] Q. W. Liu, Z. H. Yang, J. Jiang, and R. Jiang, "Icariin modulates eNOS activity via effect on post-translational protein-protein interactions to improve erectile function of spontaneously hypertensive rats," *Andrology*, vol. 9, no. 1, pp. 342–351, 2021.
- [71] T. Ashcheulova, N. Gerasimchuk, O. Kovalyova, and O. Honchar, "Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients," *Romanian Journal of Internal Medicine*, vol. 56, no. 4, pp. 257–264, 2018.
- [72] E. Yamamoto, K. Kataoka, Y.-F. Dong et al., "Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats," *PLoS One*, vol. 7, no. 6, Article ID e39162, 2012.
- [73] T. Maruhashi, J. Soga, N. Fujimura et al., "Brachial artery diameter as a marker for cardiovascular risk assessment: FMD-J study," *Atherosclerosis*, vol. 268, pp. 92–98, 2018.